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Abstract. Repurposing drugs requires ﬁnding novel therapeutic indications compared to the ones for
which they were already approved. This is an increasingly utilized strategy for ﬁnding novel medicines,
one that capitalizes on previous investments while derisking clinical activities. This approach is of interest
primarily because we continue to face signiﬁcant gaps in the drug–target interactions matrix and to
accumulate safety and efﬁcacy data during clinical studies. Collecting and making publicly available as
much data as possible on the target proﬁle of drugs offer opportunities for drug repurposing, but may
limit the commercial applications by patent applications. Certain clinical applications may be more
feasible for repurposing than others because of marked differences in side effect tolerance. Other factors
that ought to be considered when assessing drug repurposing opportunities include relevance to the
disease in question and the intellectual property landscape. These activities go far beyond the
identiﬁcation of new targets for old drugs.
KEY WORDS: drug repurposing; drug–target interactions; intellectual property; side effect tolerance;
target identiﬁcation.
There are two major “unknown unknown” categories in drug
discovery [1] that can be linked to the main reasons for failure
in drug approval, namely safety and efﬁcacy [2]. The ﬁrst
category is related to the toxicological and pharmacokinetic
proﬁles of the new molecular entity (NME), and it is mainly
addressed in phases I and IIa clinical trials, following multiple
preclinical evaluations: these evaluate the therapeutic regimen
(i.e., dose and frequency) and safety aspects concerned to the
NME. The second category relates to the protein target and
biological pathway that are subject to therapeutic interference,
and it is indirectly linked to the clinical efﬁcacy of the NME
under investigation: in this case, the question being addressed
is whether the NME-induced perturbation of the chosen
(hypothesized) target or pathway leads to the desired clinical
effect [3]. The uncertainty related to the unknown unknown
aspect of discovery is often mitigated by eliminating some of
the “unknown” elements: either the NME is well understood,
i.e., an approved drug [4], or the target/pathway is well
described, i.e., already successfully manipulated therapeuti-
cally [5]. Preferably, both “unknowns” have been addressed
previously, with the expectation that derisking the discovery
aspect may lead to a higher success rate.
The unknown unknown strategy has been rewarding, as
many blockbuster franchises have emerged following this
recipe, e.g., histamine H2 antagonists, proton pump inhibitors,
anticoagulant/antithrombotic therapy, or drugs to reduce
hypercholesterolemia [6]. However, such drugs are the result
of a long, high-cost, and high-risk optimization process, often
subject to “fast followers,”where ﬁrst-in-class does not equate
with the most ﬁnancially rewarding NME [7]. In order to
reduce time-to-market, as well as associated costs and risks,
alternative strategies have continued to emerge. In this respect,
it is currently believed (though not proven) that biologics, as
opposed to small molecules, carry a lower risk in terms of
toxicity and pharmacokinetic proﬁle [8], thus regulatory
approval milestones seem easier to reach. Therefore, one
derisking strategy is to invest in NMEs from the biologics
category. Another derisking approach is to capitalize on
previous investments, for example by taking an approved
drug that has already been optimized for safety and efﬁcacy in
a particular indication and obtain regulatory approval for novel
therapeutic applications. This is normally being referred to as
drug repurposing [9] or repositioning [4] and is the focus of
this contribution.
There is a widespread tendency in academia to assume that
drug repurposing is just about identifying new targets for old
drugs. Several aspects ought to be considered when assessing
drug repurposing opportunities, including relevance to disease,
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side effect tolerability for the new indication, and intellectual
property position. All these aspects are covered in the drug
repurposing ﬂowchart proposed in Fig. 1 and contextualized in
the following sections.
WHY DRUG REPURPOSING?
Several factors favor the drug repurposing strategy, both
at the preclinical and clinical stage [10]. One of the typical
scenarios [11] in target-directed preclinical drug discovery is
to initially focus on the optimization of binding afﬁnity for the
primary target, often with the simultaneous reduction of
afﬁnity for “secondary targets” (i.e., selectivity). Such efforts
quite often leave aside the task of target proﬁling of said drug
candidates for other, unrelated target classes, as well as drug
pharmacokinetics and safety proﬁling.
For example, once the role of cyclooxygenase 2 (COX-2)
in inﬂammation and pain was established [12], COX-2
selective agents, less active on the related enzyme cyclo-
oxygenase 1 (COX-1), were identiﬁed [13]. This was the basis
for developing celecoxib (Celebrex®), which is an order of
magnitude more potent on COX-2 compared to COX-1 [14].
Its therapeutic uses include osteoarthritis, rheumatoid arthri-
tis, juvenile rheumatoid arthritis, pain, ankylosing spondylitis,
and dysmenorrhea, as indicated on the drug label [15], and it
appears to have fewer toxicity issues compared to valdecoxib
(Vioxx®), another COX-2 selective compound. Vioxx was
withdrawn from all markets in 2004 by Merck & Co. [16].
Celebrex continues to be marketed by Pﬁzer and other
companies. A recent publisher's notice indicates that 21
reports, by one author, on the clinical efﬁcacy of these drugs
were fabricated [17]. Literature searches indicate that cele-
coxib blocks with sub-micromolar afﬁnity the dopamine
transporter [18] and MAP kinase p38 alpha [17] and is a
nanomolar inhibitor of carbonic anhydrase [19]. Despite these
unusual off-target activities, there are no adverse events
particular to celecoxib, when compared to diclofenac, nap-
roxen, and ibuprofen, in controlled pre-marketing clinical
trials [15].
However, the lack of completeness in the knowledge of
drug–target interaction proﬁles [20], in particular for older
drugs, creates opportunities for repurposing of already-ap-
proved drugs for novel therapeutic indications through the
discovery of biologically and clinically relevant afﬁnities for new
targets, which play a determinant role in those indications
(Fig. 1). Novel computational methods, which can estimate the
target proﬁle of small molecules with increasing levels of recall
and precision, have signiﬁcantly increased the scope of target
space that can be explored, thus facilitating the identiﬁcation of
new targets for old drugs [21–23].
The other advantage is that the NME subject to
repositioning is an already-approved drug, and thus, there is
no need to conduct phase I and phase IIa clinical trials. This is
more likely to be the case for drugs being repurposed at
similar or lower dosage compared to the maximum dose that
has already been approved by regulatory agencies [24]. The
large body of clinical data and experience accumulated in
phase III (efﬁcacy) and phase IV (post-marketing) trials for
the drug in question offer a good understanding of its proﬁle
in terms of adverse events, long-term and chronic toxicity, as
well as on- and off-label effects. In general, a large literature
corpus for a particular drug is regarded as beneﬁcial since,
despite potential shortcomings, the clinical observation and
monitoring required (in particular in high-risk situations) is
manageable. When repurposing an older drug, it is generally
anticipated that costs associated with its synthesis (including
potential hazardous waste) have already been addressed,
which turn the therapeutic management of the new indica-
tions economically attractive. Last, but not least, repurposing
may extend the patent life (i.e., market exclusivity) for
successful drug franchises, a pathway that has been explored
by several major pharmaceutical companies.
Overall, the lack of data completeness during the
preclinical phases together with the accumulation of safety
and efﬁcacy data during the various clinical phases offers a
wealth of opportunities for drug repurposing. Accordingly,
collecting and making publicly available as much data as
possible on the target proﬁle of drugs would limit the
possibilities of repurposing from competitors.
WHICH THERAPEUTIC AREAS?
The identiﬁcation of novel targets that interact with
marketed drugs is the ﬁrst step in assessing the repurposing
potential. A drug–target interaction is generally, though not
always, considered biologically relevant if its activity is equal
or better than 1 μM, that is pAct ≥6, where “pAct” is the
negative logarithm of biochemical or pharmacological in vitro
assay values (mainly, pKi, pKb, pKd, pIC50, or pEC50).
However, the therapeutic relevance of these drug–target
interactions is highly dependent on the strength of the
experimental evidence associating said target perturbation
within the clinical context of a particular disease (Fig. 1).
Several public sources provide gene–disease associations
[25,26]. Access to this information allows for deﬁning the
target space relevant for all diseases within a given therapeu-
tic area, which in turn serves as the basis for identifying
targets that have been linked to multiple diseases in various
therapeutic areas. For example, it is widely accepted that class
A aminergic G protein-coupled receptors (GPCRs) are
closely associated with diseases of the central nervous system
[27]. However, members of this GPCR subclass play a role in
cardiovascular diseases [28] and oncology [29] as well.
An overlooked aspect that plays a critical role in drug
repurposing is the level of patient compliance with respect to
side effect tolerance, which differs widely according to the
therapeutic area (Fig. 1). Side effects that are acceptable in
some therapeutic areas, e.g., for therapeutic drugs prescribed
for life-threatening conditions (such as cancer), are unaccept-
able in other therapeutic areas, where quality of life becomes
central to patient compliance (such as central nervous
system). For example, celecoxib has been repurposed [4]
from osteoarthritis to familial colorectal polyps [30] and
colorectal cancer [31]. The practical consequence with respect
to drug repurposing is that certain clinical applications may
be more feasible than others because of marked differences in
side effect tolerance. Accordingly, it may be easier to
repurpose a neurological drug than an anticancer drug. This
statement is substantiated by a recent survey on drugs
approved for new indications up to 2004 [4]. Among a list
of 26 repurposed drugs, 12 were neurological drugs (46%),
whereas only two were anticancer drugs (8%).
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WHAT CAN BE REPURPOSED?
An intriguing aspect related to the derisking strategy
involving already-approved drugs is the intellectual property
landscape. Frequently, drug repurposing focuses on drugs for
which patent rights on matter and/or indication have expired.
This has become increasingly facilitated by the availability of
commercial chemical libraries composed of out-of-patent drugs
[32]. For those drugs still covered by existing patents, completely
novel therapeutic applications are sought. Some may argue that
composition-of-matter patents are required to gain market
exclusivity. However, Celgene successfully repurposed thalido-
mide (Thalomid®) for leprosy, and Merz repurposed meman-
tine for Alzheimer's disease, as Ebixa®. Thus, based on
appropriate licensing, repurposing drugs that are still under
intellectual property coverage is possible [33]. Another ap-
proach is to replace hydrogen with deuterium at speciﬁc
positions, and several deuterated versions of approved drugs
are currently undergoing clinical trials [34].
For more modern medicines that have been optimized
over a length of time for a particular target (or indication),
one cannot expect successful repositioning for a narrow
therapeutic domain, unless selectivity is not an issue. More
complex therapeutic areas, such as central nervous system
linked mainly to aminergic GPCRs and oncology linked
mainly to kinases, are somewhat easier to identify for
approved drugs, since there is a wider array of targets and
pathways that can be subjected to NME-related perturbation.
Furthermore, the probability of highly similar ligands to bind
two distinct targets, also referred to as cross-pharmacology,
needs to be assessed for the primary target(s) of a launched
drug, since different target families have been shown to have
different levels of cross-pharmacology [35]. For example,
GPCRs have a higher degree of cross-pharmacology among
its members compared to enzymes, ligand-gated ion channels,
or nuclear receptors. In addition, cross-pharmacology be-
tween some GPCRs and non-GPCR proteins has been also
detected [36]. Taking into consideration the fact that some
GPCRs are linked to multiple therapeutic areas (vide supra),
drugs targeting aminergic GPCRs could constitute privileged
starting points for drug repurposing. Indeed, at least 10 out of
26 repurposed drugs (38%) reviewed recently [4] have known
interactions to aminergic GPCRs.
WHO'S WHO IN DRUG REPURPOSING
The outsourcing trend and the overall reduction of in-
house workforce have caused a mass migration of skilled and
experienced scientists from pharmaceutical industry to aca-
demia. The net effect of this trend has been an increased
transfer of drug discovery know-how to academia, which
effectively has shifted a large percentage of drug discovery
and repurposing activities from the industrial to the academic
sector. Against this backdrop, we anticipate that academia
will foster most innovative efforts in drug repurposing in the
immediate future. Critical to this process is the ability to
pursue novel indications in the context of clinical trials.
Despite the current enthusiasm, there remains an unmet
critical need to fund repurposing projects into phase IIb and
phase III. The burden of proof remains with the petitioner, be
Fig. 1. Flowchart for drug repurposing beyond identifying new targets for old drugs. The abbreviation “db” stands for “database”
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it academic or industrial, which implies that any claims for
clinical effectiveness against disease have to be demonstrated in
clinically controlled conditions. Academic groups will have to
initiate and conduct clinical trials, some of which are likely to be
developed in partnership with the industrial sector. Thus, several
types of repurposing models emerge: large pharmaceutical
houses, major clinical enterprises, governmental facilities, and
consortia involving (mostly) academic groups in partnership
with industry interested in niche therapeutic areas. Recent
strategic approaches and individual companies that currently
engage in drug repurposing as their primary business platform
have been reviewed elsewhere [37].
CONCLUSIONS
While the process of drug rescue and repurposing has
receiving increased attention at the National Institutes of
Health [38], this strategy is not without risks, in particular for
the industrial sector. Indeed, when all pertinent factors are
taken into consideration, drug repurposing may ultimately
incur high costs, which may reduce even further the already
diminishing resources of the pharmaceutical industry. On one
hand, drugs are typically the result of a long optimization
process directed to improve the afﬁnity and selectivity
(among other aspects) for a given primary target. Thus, the
potency values for novel targets identiﬁed for old drugs will
likely be lower than the potency for the primary target. As a
consequence, one should conduct repurposing efforts for a
target/indication that was not deliberately counter-selected
during the initial project. If other drugs are already approved
for that indication, demonstrating superiority with respect to
efﬁcacy and safety (phases III and IV) may be an insur-
mountable challenge [39]. According to a recent reproduc-
ibility analysis of 67 target validation studies, target–disease
associations are not always fully reliable [40]. Therefore, the
risks of having a second-in-class drug with lower potency that
is not unambiguously linked to a certain indication should be
appropriately balanced.
On the other hand, one ought to consider that the
speciﬁcity (in a statistical sense) of current approaches to
suggest drugs for repurposing is relatively low. Recent
academic enthusiasm in this ﬁeld has resulted in the
publication of relatively long lists of drugs that could
potentially be repurposed for a variety of indications,
including tuberculosis [41], breast and prostate cancer, and
myelogenous leukemia [42]. This academic trend has two
(unfortunate) consequences. As this information is now
public domain, even if experimentally conﬁrmed, it still
constitutes “prior art.” This effectively blocks intellectual
property protection and future investment in that particular
combination of drugs and targets or clinical indications.
Equally important, it lowers the credibility of computational
approaches to drug repurposing, since it is not likely that
many of these suggestions can lead to regulatory approval,
which remains the only milestone for successful drug repur-
posing. It seems unrealistic to follow-up on all the candidates
being claimed for repurposing. Rather, substantiating the
relevance of all potential repurposing drugs for a given
indication is likely to be a long and costly process. Taking
into consideration all aspects highlighted above, the ideal
candidate for a repurposing initiative would be an off-patent
safe drug for which a novel target has been identiﬁed, with
afﬁnity within the maximum recommended therapeutic dose for
an already-approved indication, and linked with strong support-
ing evidence to a therapeutically unmet need or rare disease.
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